Ophthalmology

Explore the complexities of Ophthalmology research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against Ophthalmology with flcube.com.

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody
CompanyDeals

BioPartners X Signs RMB 227 Million Technology Transfer Deal with CAMS for CD132 Autoimmune Antibody

BioPartners X announced that it has entered into a technology transfer agreement with the Hospital of Dermatology, Chinese Academy of Medical Sciences (CAMS) for an innovative CD132‑targeting monoclonal antibody, with…

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Zhejiang Garden Biopharmaceutical and Guangzhou National Laboratory Form Joint Venture to Develop 25‑Hydroxycholesterol – A Prodrug‑Class Broad‑Spectrum Antiviral Program

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Adalvo and Jiangsu Sinopep‑Allsino Forge Strategic Partnership – Combining Peptide and Oligonucleotide Manufacturing Expertise with Commercial Reach Across 160+ Markets

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody
CompanyDeals

Minghui Pharmaceutical Strikes Exclusive Japan License Deal with ASKA for MHB018A – $110 Million Upfront, Up to $330 Million in Milestones and Mid‑30 % Royalties for Thyroid Eye Disease Antibody

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio
CompanyDeals

Alcon Acquires Neurotech Pharmaceuticals for USD 550 Million – Deal Brings ENCELTO, First FDA‑Approved MacTel Type 2 Therapy, Into Retina Portfolio

EyePoint's DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met
CompanyDrug

EyePoint’s DURAVYU Misses Primary Endpoint in Phase III LUCIA Trial for Wet AMD – Non‑Inferiority vs. Aflibercept Not Achieved; Key Secondary Endpoints Met

FDA Approves Roche's Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment
CompanyDrug

FDA Approves Roche’s Enspryng for Thyroid Eye Disease – Satralizumab Becomes First and Only At‑Home Subcutaneous TED Treatment

FDA Approves Viatris's RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label
CompanyDrug

FDA Approves Viatris’s RYZUMVI for Presbyopia – Phentolamine Ophthalmic Solution 0.75% Adds Age‑Related Vision Indication to Existing Mydriasis Label

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection
CompanyDeals

Harbin Gloria Pharmaceuticals Acquires Capital Medical University Patent for RMB 11.15 Million – Backing First‑in‑Class TLK2 Gene Therapy for Glaucoma Neuroprotection

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy
CompanyDeals

Wuhan Hiteck Licenses HT006.2.2 rhNGF Eye Drops to Visara for Ex‑Greater China – Up to USD 111 Million Deal Advances Next‑Generation Neurotrophic Keratitis Therapy

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement
CompanyDrug

Genentech Reports One‑Year Phase III Data for Vamikibart in Uveitic Macular Edema – MEERKAT and SANDCAT Support Rapid, Sustained Vision Improvement

Show More